Abstract
To characterize diffuse large B-cell lymphoma (DLBCL) with chromosome 7 gains, we combined clinical data with genomic, RNA and miRNA profiling. Gains were associated with age >60 years, female gender, a trend for higher complete response rate, lower death rate, and better overall survival in patients treated with R-CHOP. Lesions were inversely associated with bone marrow involvement and number of extra-nodal sites. Differentially expressed transcripts were enriched of genes belonging to specific pathways and miRNAs targets. MIR96, MIR182, MIR589, MIR25 were shown significantly up-regulated in 7q+ DLBCL by real-time PCR.
© 2011 Blackwell Publishing Ltd.
Publication types
-
Multicenter Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chromosome Duplication*
-
Chromosomes, Human, Pair 7 / genetics*
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Follow-Up Studies
-
Gene Expression Profiling / methods
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Male
-
MicroRNAs / genetics
-
Middle Aged
-
Prednisone / therapeutic use
-
Prognosis
-
RNA, Neoplasm / genetics
-
Rituximab
-
Survival Analysis
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
MicroRNAs
-
RNA, Neoplasm
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone